These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15283108)

  • 1. [Should chemotherapy or endocrine therapy be used as first choice in patients with advanced breast cancer? A status article based on the Cochrane analysis "Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer"].
    Ejlertsen B; Mouridsen H
    Ugeskr Laeger; 2004 Jun; 166(25):2434-6. PubMed ID: 15283108
    [No Abstract]   [Full Text] [Related]  

  • 2. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer.
    Stockler M; Wilcken NR; Ghersi D; Simes RJ
    Cancer Treat Rev; 2000 Jun; 26(3):151-68. PubMed ID: 10814559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience.
    Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF
    Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [High dose chemotherapy versus conventional chemotherapy in metastasing breast cancer. An analysis of a systematic Cochrane review].
    Nielsen DL; Svane IM
    Ugeskr Laeger; 2004 Nov; 166(46):4145-7. PubMed ID: 15565848
    [No Abstract]   [Full Text] [Related]  

  • 5. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer.
    Andre F; Hatzis C; Anderson K; Sotiriou C; Mazouni C; Mejia J; Wang B; Hortobagyi GN; Symmans WF; Pusztai L
    Clin Cancer Res; 2007 Apr; 13(7):2061-7. PubMed ID: 17404087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review].
    Nielsen DL; Svane IM
    Ugeskr Laeger; 2004 Nov; 166(46):4148-50. PubMed ID: 15565849
    [No Abstract]   [Full Text] [Related]  

  • 7. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH; Silverman P; Lasheen W; Meinert J; Siminoff LA
    Breast Cancer Res Treat; 2007 May; 102(3):301-12. PubMed ID: 17033926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the treatment of metastatic breast cancer.
    Gralow JR
    Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical treatment of early breast cancer: chemotherapy].
    Ejlertsen B; Kamby C
    Ugeskr Laeger; 2007 Sep; 169(37):3070-2. PubMed ID: 17877950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
    Adjuvant Breast Cancer Trials Collaborative Group
    J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer.
    Gligorov J; Lotz JP
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():53-66. PubMed ID: 19101794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adjuvant systemic therapy of breast carcinoma].
    Wickramanayake PD; Katay I; Josting A; Diehl V
    Med Klin (Munich); 1996 Oct; 91(10):646-53. PubMed ID: 9019642
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonhormonal systemic therapy for advanced breast cancer: do the math!
    Bedard PL; Piccart-Gebhart MJ
    J Natl Cancer Inst; 2008 Dec; 100(24):1745-7. PubMed ID: 19066269
    [No Abstract]   [Full Text] [Related]  

  • 16. Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.
    Yamashita H; Nishio M; Ando Y; Zhang Z; Hamaguchi M; Mita K; Kobayashi S; Fujii Y; Iwase H
    Endocr Relat Cancer; 2006 Sep; 13(3):885-93. PubMed ID: 16954437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemotherapy for metastatic breast cancer].
    Schmid P; Possinger K
    Zentralbl Gynakol; 2006 Dec; 128(6):318-26. PubMed ID: 17213969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M; Leonard RC; Barnadas A; Marangolo M; Untch M; Malamos N; Mayordomo J; Reichert D; Pedrini JL; Ukarma L; Scherhag A; Burger HU
    J Clin Oncol; 2008 Feb; 26(4):592-8. PubMed ID: 18235117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.